Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort

Sylvia Binck; Claire Pauly; Michel Vaillant; Geraldine Hipp; Manon Gantenbein; Rejko Krueger; Nico J Diederich

doi:10.3389/fneur.2020.578924

Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort

Front Neurol. 2020 Nov 12:11:578924. doi: 10.3389/fneur.2020.578924. eCollection 2020.

Authors

Sylvia Binck^{1

2}, Claire Pauly^{1

2}, Michel Vaillant³, Geraldine Hipp¹, Manon Gantenbein³, Rejko Krueger^{1

2

3}, Nico J Diederich²

Affiliations

¹ Luxembourg Centre for System Biomedicine, University of Luxembourg, Luxembourg, Luxembourg.
² Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
³ Luxembourg Institute of Health, Luxembourg, Luxembourg.

Abstract

Background: To establish the frequency of impulse control disorder (ICD) in Parkinson's disease (PD). Methods: Within the Luxembourg Parkinson's Study, PD patients were evaluated for ICD presence (score ≥ 1 on MDS-UPDRS I item 1.6), use of dopamine agonists (DA) and other medications. Results: 470 patients were enrolled. Among 217 patients without DA use, 6.9% scored positive for ICD, vs. 15.4% among 253 patients with DA use (p = 0.005). The regression analysis showed that age at PD diagnosis had only a minor impact on ICD occurrence, while there was no influence by gender or co-medications. The longitudinal study over 2 years in 156 patients demonstrated increasing ICD frequency in DA users (p = 0.005). Conclusion: This large and non-interventional study confirms that PD patients with DA treatment show higher frequency of ICD than patients without DA use. It newly demonstrates that ICD can develop independently from age, gender, or co-medications.

Keywords: Parkinson's disease (PD); dopamine agonists; impulse control disorder; longitudinal analysis; risk factors.